Department of Radiation Oncology, Beaumont Cancer Institute, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA.
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):134-8. doi: 10.1016/j.ijrobp.2013.05.030.
To examine clinical outcomes of accelerated partial-breast irradiation (APBI) stratified by the number of American Society for Radiation Oncology consensus statement cautionary/unsuitable risk factors (RFs) present.
A total of 692 patients were treated with APBI at a single institution between April 1993 and January 2012 using interstitial (n=195), balloon (n=292), and 3-dimensional conformal radiation therapy (n=205) techniques. Clinical outcomes were evaluated by risk group and number of RFs.
Median follow-up was 5.2 years (range, 0-18.3 years). Most patients were classified as suitable (n=240, 34%) or cautionary (n=343, 50%) risk, whereas 16% (n=109) were unsuitable. In patients with increasing total RFs (1 RF, 2 RF, 3+ RF), higher rates of grade 3 histology (10% vs 18% vs 32%, P<.001), estrogen receptor negativity (0 vs 12% vs 29%, P<.001), close/positive margins (0 vs 6% vs 17%, P<.001), and use of adjuvant chemotherapy (3% vs 12% vs 33%, P<.001) were noted. When pooling cautionary and unsuitable patients, increased ipsilateral breast tumor recurrence/regional recurrence was most notable for patients with 3 or more combined RFs versus 2 or fewer combined RFs (P<.001).
Patients with 3 or more cautionary or unsuitable RFs may be at risk for higher local, regional, and distant recurrence after breast-conserving therapy using APBI. Patients with 2 or fewer total RFs have 98% locoregional control at 5 years. Inclusion of total number of RFs in future risk stratification schemes for APBI may be warranted.
通过考察美国放射肿瘤学会共识声明中警示/不适宜风险因素(RFs)的数量,来研究加速部分乳房照射(APBI)的临床结果。
1993 年 4 月至 2012 年 1 月,一家机构对 692 例患者采用间质内(n=195)、气囊(n=292)和 3 维适形放射治疗(n=205)技术进行 APBI 治疗。通过风险组和 RF 数量评估临床结果。
中位随访时间为 5.2 年(范围,0-18.3 年)。大多数患者被归类为适宜(n=240,34%)或警示(n=343,50%)风险,而 16%(n=109)为不适宜。RF 总数增加(1 RF、2 RF、3+ RF)的患者中,组织学 3 级比例更高(10%比 18%比 32%,P<.001),雌激素受体阴性比例更高(0 比 12%比 29%,P<.001),切缘/阳性比例更高(0 比 6%比 17%,P<.001),以及辅助化疗使用率更高(3%比 12%比 33%,P<.001)。当合并警示和不适宜患者时,3 个或更多联合 RFs 的患者同侧乳房肿瘤复发/区域复发风险最高,而 2 个或更少联合 RFs 的患者则最低(P<.001)。
接受 APBI 保乳治疗的患者,若存在 3 个或更多警示或不适宜 RFs,则局部、区域和远处复发的风险可能更高。若 RFs 总数为 2 个或更少,则 5 年局部区域控制率为 98%。将来的 APBI 风险分层方案中可能需要包含 RFs 的总数。